

Number of Authorised Prescribers approved to prescribe Medicinal Cannabis  
 Number of AP approvals (product)  
 Total patients via AP pathway including indication and 6 monthly reporting numbers

From 1 August 2017 to 31 October 2019	From 1 July 2017 to 30 June 2019 For periods ending: 31 December 2017 30 June 2018 31 December 2018 30 June 2019
80	
204	
	555

**Total patients via AP pathway including indication and 6 monthly reporting numbers**

anticonvulsant for children (&lt;18 years) with severe refractory epilepsy

Cancer Pain

Cancer pain and or palliation, Chronic non-cancer pain (CNCP)

Cancer pain and symptom management

Cancer related pain +/- nausea and vomiting related to cancer treatment, Neuropathic pain, Insomnia, Anxiety, Restless Legs Syndrome, agitation and the behavioural and psychological symptoms of dementia

Cancer related pain +/- nausea and vomiting,

Chronic debilitating non-cancer pain

Cancer related pain and Chronic non-cancer pain

Cancer related pain, Cancer related nausea and vomiting, Neuropathic pain/fibromyalgia, Insomnia, Anxiety, Restless Legs Syndrome, Agitation and/or the behavioural and psychological symptoms of dementia

Cancer related pain, Chronic non cancer pain, Neuropathic pain associated with MS

Cancer related pain, Chronic non cancer pain, Neuropathic pain associated with MS

Chronic pain

Cancer related pain, Neuropathic pain, PTSD, insomnia

Chemotherapy induced nausea and vomiting

Chemotherapy induced nausea and vomiting

Pain, cachecia, and/or insomnia associate with cancer in palliative care

Chemotherapy induced vomiting

Chronic pain

Chronic pain, Cancer related pain +/- nausea and vomiting

Chronic pain, MS Spasticity, neuropathic pain, sleep disturbances, CINV, PTSD

Chronic persistent non-cancer related pain

chronic persistent non-cancer related pain, refractory to standard pain medications

Compassionate access to medicinal cannabis products, a small group of children with very severe intractable epilepsy.

Compassionate access to medicinal cannabis products, a small group of children with very severe intractable epilepsy. Patients must meet the inclusion criteria and are approved by an independent panel of the Office of Medicinal Cannabis, DHHS VIC.

Continuation of CAPS Pilot trial for young people with Refractory Anxiety disorders

Intractable Epilepsy

Neuropathic pain, PTSD, insomnia

New Patients initiated 01/07/17-31/12/17	New Patients initiated 01/01/18-30/06/18	New Patients initiated 01/07/18-31/12/18	New Patients initiated 01/01/19-30/06/19
0	0	2	0
0	0	0	0
0	0	0	10
0	0	43	8
0	0	0	0
0	0	10	30
0	0	0	0
0	0	2	0
0	0	5	7
0	0	36	0
0	0	1	4
0	0	0	0
0	0	3	0
1	23	10	0
0	1	26	0
0	0	13	0
0	0	0	0
0	0	0	0
0	0	0	0
0	0	0	0
0	0	0	0
0	0	0	0
0	1	8	0
0	0	0	0

Non-cancer pain (neuropathic pain)	0	0	0	1
Non-cancer pain (neuropathic pain)				
Cancer -related pain				
Chemotherapy-Induced Nausea & Vomiting (CINV)	0	0	0	0
Non-cancer pain (neuropathic pain), Cancer-related pain or Chemotherapy-Induced Nausea & Vomiting (CINV)	2	0	23	1
Non-cancer pain, cancer related pain and CINV	0	0	0	0
Palliative care patients with anorexia, weight loss, refractory chemotherapy induced nausea and vomiting	1	1	0	0
Patient meets the inclusion criteria and are approved by an independent panel of the Office of Medicinal Cannabis, DHHS VIC				
	0	1	1	0
Patients with advanced histologically proven cancer (metastatic or locally advanced)	0	0	0	0
Patients with chronic persistent non cancer related pain	0	21	10	20
patients with intractable cancer pain with or without chemotherapy-induced nausea and vomiting, when all other treatment and management strategies have not completely resolved symptoms, failed, contraindicated or have caused side effects				
	0	0	0	0
Refractory Epilepsy	0	0	1	0
Refractory Paediatric Epilepsy	89	105	2	0
Second line therapy for the management of intractable pain in advanced cancer patients, as an adjunct to opioid analgesia				
	0	9	15	0
Severe Refractory Epilepsy	0	0	8	0
Use as anticonvulsant for group of 40 eligible children (<18 years) with severe, refractory epilepsy.	0	0	0	0
<b>Total for each period</b>	<b>93</b>	<b>162</b>	<b>219</b>	<b>81</b>

## Total SAS B approvals by State and per Indication

Indication / State	Not listed	ACT	NSW	NT	QLD	SA	TAS	VIC	WA	Grand Total
Achalasia			1							1
ADHD - Attention deficit disorder with hyperactivity			1		21					22
Aggressive behaviour					5	1		1		7
Agitation									1	1
Alzheimers dementia			1					7		8
Alzheimer's disease			6		4			10	6	26
Amyotrophic lateral sclerosis			3					1		4
Anaemia					1					1
Anorexia			181		42	6	1	7	7	244
Anxiety		3	336		533	11		286	18	1187
Appetite			2		7	1				10
Appetite control			2		1				2	5
Arthritis						2				2
Atopic dermatitis					2			2		4
Autism			13		26	2		5	1	47
Autism spectrum disorder		1	23		36	11		27	1	99
Behaviour management			2							2
Behavioural problem			2		2	3		3	1	11
Bipolar			1							1
Blood glucose management					1					1
Cachexia			2		3	1		2		8
Cancer pain and symptom management		41	543		607	41	1	386	89	1708
Chemotherapy induced vomiting			85		45	7		46	3	186
Chemotherapy-induced nausea and vomiting			3		12					15
Chronic pain	1	52	3262	4	5949	93		2537	707	12605
Complex regional pain syndrome (CRPS)			1					3		4
COPD			1		2					3
Crohn's disease			3		3			4		10
Dementia			4		6			9	2	21
Depression			7		3			3		13
Dermatitis					1					1

Indication / State	Not listed	ACT	NSW	NT	QLD	SA	TAS	VIC	WA	Grand Total
Dyskinesia			1		1				1	3
Dyspnea					3					3
Dystonia			4		53			6	1	64
Epilepsy			33		12	7	10	46	39	147
Essential tremor								1		1
Fibromyalgia			15		8	3		78	6	110
Generalised anxiety disorder			5		2			2		9
Glioblastoma						4	2	6		12
Glioblastoma multiforme						1				1
Glioma						1		1		2
Grover's disease			1							1
Headache									1	1
Huntington chorea			1		2				10	13
Irritable bowel syndrome			3		1			3		7
Inflammatory bowel disease			5		7			20		32
Insomnia			50		132	1		45	10	238
Irritable bowel syndrome			2		2			6		10
Joint pain			1					1		2
Kearns-Sayre mitochondrial cytopathy			1							1
Memory loss									1	1
Meniere disease								1		1
Migraine			21		2			7		30
Migraine (disorder)			15		8			56	1	80
Mood disorder			6		8	2		10		26
Motor neurone disease			2		1				2	5
Movement disorder			17		8	1		6	1	33
Multiple sclerosis			29		22	2		21	17	91
Multiple sclerosis spasm and pain		1	13		21			8		43
Muscle rigidity			3							3
Muscle spasm			1		1	1				3
Muscle spasticity			1					2		3
Muscle wasting			1							1

Indication / State	Not listed	ACT	NSW	NT	QLD	SA	TAS	VIC	WA	Grand Total
Muscular dystrophy								1		1
Myoclonic disorder			2		1			1		4
Nausea			26		7	17		13	2	65
Nausea and vomiting			5		9	7		2		23
Neuralgia								1		1
Neurological disorder			1							1
Neuropathic pain		7	913	1	286	35		187	294	1723
Neuropathy			1						2	3
Oscillopsia								1		1
Osteoarthritis			1							1
Pain		1	57		7	8		28	12	113
Palliative						1		1		2
Palliative care			9		37	4		53	4	107
Panic disorder								2		2
Parkinson's disease		1	32		43			54	21	151
Peripheral neuropathy						1				1
Pityriasis rubra pilaris					1					1
Post-traumatic stress disorder			68		152	6		51	19	296
Psoriasis					1					1
Progressive supranuclear palsy									6	6
Psychogenic seizures			1							1
Refractory epilepsy		1	3		4	1		9	7	25
Refractory nausea and vomiting			2		1					3
Restless legs					2			2		4
Restless legs syndrome			7		2			5		14
Rheumatoid arthritis			3					3		6
Schizophrenia					4					4
Seizure			2		2	3		2	8	17
Seizure management		1	167		158	47	8	111	124	616
Sleep disorder			20		19			10	9	58
Sleep disturbance			4		1					5
Social anxiety disorder					1					1

Indication / State	Not listed	ACT	NSW	NT	QLD	SA	TAS	VIC	WA	Grand Total
Spasticity			111		65	1		12	13	202
Tinnitus					2					2
Tourette's disorder			1							1
Tourette's syndrome			15		6			2		23
Tremor			8		15			9	7	39
Trigeminal neuralgia			1					5		6
Ulcerative colitis			3		2			12	1	18
Grand Total	1	109	6179	5	8434	333	22	4242	1457	20782